{"title":"Can biomarkers predict chemosensitivity in CRS-HIPEC patients?","authors":"Josephine Hendrikson, J. Tan, C. Ong","doi":"10.2217/crc-2019-0015","DOIUrl":"https://doi.org/10.2217/crc-2019-0015","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/crc-2019-0015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49491878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chukwuemeka Ihemelandu, Aisha Naeem, Erika Parasido, Deborah Berry, Krysta Chaldekas, Brent T Harris, Olga Rodriguez, Christopher Albanese
Aim: To analyze the clinicopathologic and prognostic significance of Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a cancer stem cell marker expression in a cohort of colorectal cancer patients (CRC).
Patients & methods: A total of 76 formalin-fixed paraffin-embedded tissue blocks of primary or metastatic tumors from 49 CRC patients were collected for duration 2009-2015. LGR5 expression was assessed through immunohistochemical staining of a tissue microarray.
Results: LGR5 was significantly over expressed in CRC tissue samples and found to be a statistically significant independent prognostic marker for an improved overall survival.
Conclusion: LGR5 expression was higher in colorectal cancer than in normal tissue. LGR5 was an independent prognostic marker for better clinical outcomes and might be used as a potential therapeutic target in CRCs.
{"title":"Clinicopathologic and prognostic significance of LGR5, a cancer stem cell marker in patients with colorectal cancer.","authors":"Chukwuemeka Ihemelandu, Aisha Naeem, Erika Parasido, Deborah Berry, Krysta Chaldekas, Brent T Harris, Olga Rodriguez, Christopher Albanese","doi":"10.2217/crc-2019-0009","DOIUrl":"https://doi.org/10.2217/crc-2019-0009","url":null,"abstract":"<p><strong>Aim: </strong>To analyze the clinicopathologic and prognostic significance of Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a cancer stem cell marker expression in a cohort of colorectal cancer patients (CRC).</p><p><strong>Patients & methods: </strong>A total of 76 formalin-fixed paraffin-embedded tissue blocks of primary or metastatic tumors from 49 CRC patients were collected for duration 2009-2015. LGR5 expression was assessed through immunohistochemical staining of a tissue microarray.</p><p><strong>Results: </strong>LGR5 was significantly over expressed in CRC tissue samples and found to be a statistically significant independent prognostic marker for an improved overall survival.</p><p><strong>Conclusion: </strong>LGR5 expression was higher in colorectal cancer than in normal tissue. LGR5 was an independent prognostic marker for better clinical outcomes and might be used as a potential therapeutic target in CRCs.</p>","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"8 4","pages":"CRC11"},"PeriodicalIF":4.2,"publicationDate":"2019-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/crc-2019-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37628017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Asadi, Shoan Taheri Talesh, M. Gjerstorff, D. Shanehbandi, B. Baradaran, S. Hashemzadeh, V. Zafari
Aim: miRNAs control biological processes that are implicated in carcinogenesis, and have been researched as potential biomarkers for colorectal cancer (CRC). The aim of the current study was to evaluate the miRNA expression profile in CRC patients to determine their potential to be used as biomarkers in the disease. Materials & methods: Total 47 tissues and their matched marginal tissues, as control group, were obtained from CRC patients. The transcript levels of a selected panel of 15 cancer-associated miRNAs were quantified via real-time gene expression method. Results: miR-155, miR130a, miR-181b, miR-196a, miR-200c and miR-224 were significantly upregulated, while miR122, miR-132, miR-203b, miR330, miR-323, miR-378a-3p and miR-598 we significantly downregulated in CRC. Conclusion: We identified a panel of miRNAs that may be involved in the etiology and pathogenesis of CRC, and may be used for novel diagnostic and therapeutic strategies.
{"title":"Identification of miRNAs correlating with stage and progression of colorectal cancer","authors":"M. Asadi, Shoan Taheri Talesh, M. Gjerstorff, D. Shanehbandi, B. Baradaran, S. Hashemzadeh, V. Zafari","doi":"10.2217/crc-2018-0014","DOIUrl":"https://doi.org/10.2217/crc-2018-0014","url":null,"abstract":"Aim: miRNAs control biological processes that are implicated in carcinogenesis, and have been researched as potential biomarkers for colorectal cancer (CRC). The aim of the current study was to evaluate the miRNA expression profile in CRC patients to determine their potential to be used as biomarkers in the disease. Materials & methods: Total 47 tissues and their matched marginal tissues, as control group, were obtained from CRC patients. The transcript levels of a selected panel of 15 cancer-associated miRNAs were quantified via real-time gene expression method. Results: miR-155, miR130a, miR-181b, miR-196a, miR-200c and miR-224 were significantly upregulated, while miR122, miR-132, miR-203b, miR330, miR-323, miR-378a-3p and miR-598 we significantly downregulated in CRC. Conclusion: We identified a panel of miRNAs that may be involved in the etiology and pathogenesis of CRC, and may be used for novel diagnostic and therapeutic strategies.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"1 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/crc-2018-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42415876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical implications of STAT6 mRNA and protein knockdown in human colon adenocarcinoma cell line, HT-29","authors":"C. Salguero-Aranda, Daniel Sancho-Mensat","doi":"10.2217/CRC-2019-0004","DOIUrl":"https://doi.org/10.2217/CRC-2019-0004","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2019-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44581986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Rachdi, S. Labidi, N. Mejri, H. Benna, N. Daoud, R. Bayar, A. Marghli, M. Khalfallah, H. Boussen
Aim: Surgical treatment of hepatic or pulmonary metastases is the optimal therapeutic goal in metastatic colorectal cancer (CRC). Methods: Our retrospective study concerned 70 patients treated for CRC, collected from 2003 to 2015, presenting liver metastases (LM) in 61 cases and pulmonary metastases (PM) in nine cases, treated by surgery for their distant disease. We collected and compared their epidemiologic, anatomoclinical parameters and analyzed several prognostic factors. Results: Metastases were multiple (≥ 4) in 9/61 LM and in 5/9 PM. Patients had synchronous metastases in 32 cases (30 LM/2 PM) and metachronous metastases in 33 cases (32 LM and 11 PM). Surgery for LM consisted of metastasectomy (49/61), segmentectomy (5/61) and hepatectomy for the remaining seven patients; ten patients had also subsequent liver radiofrequency. LM were treated by wedge resection in 6/9 and lobectomy in two cases, radiofrequency was performed in five cases. 56/61 (80%) patients received chemotherapy, mostly FOLFOX protocol as the first-line treatment and targeted therapy in 55% of cases. For the overall population, median OS and PFS were, respectively, 44 and 32 months. We did not observe any significant difference in terms of OS (p = 0.659) and PFS (p = 0.318) between resected LM or/and PM. A better survival was found when there was disease-free interval between the occurrence of the primary and the metastases exceeded 18 months and in patients with less than four metastases. Conclusion: Resection of metastatic disease mostly in liver and lungs improves survival of patients with CRC. The patients with longer disease-free interval and less than four metastases had the best outcomes.
{"title":"Local treatment of liver and lung metastases from colorectal cancer: a multicenter Tunisian study","authors":"H. Rachdi, S. Labidi, N. Mejri, H. Benna, N. Daoud, R. Bayar, A. Marghli, M. Khalfallah, H. Boussen","doi":"10.2217/CRC-2018-0002","DOIUrl":"https://doi.org/10.2217/CRC-2018-0002","url":null,"abstract":"Aim: Surgical treatment of hepatic or pulmonary metastases is the optimal therapeutic goal in metastatic colorectal cancer (CRC). Methods: Our retrospective study concerned 70 patients treated for CRC, collected from 2003 to 2015, presenting liver metastases (LM) in 61 cases and pulmonary metastases (PM) in nine cases, treated by surgery for their distant disease. We collected and compared their epidemiologic, anatomoclinical parameters and analyzed several prognostic factors. Results: Metastases were multiple (≥ 4) in 9/61 LM and in 5/9 PM. Patients had synchronous metastases in 32 cases (30 LM/2 PM) and metachronous metastases in 33 cases (32 LM and 11 PM). Surgery for LM consisted of metastasectomy (49/61), segmentectomy (5/61) and hepatectomy for the remaining seven patients; ten patients had also subsequent liver radiofrequency. LM were treated by wedge resection in 6/9 and lobectomy in two cases, radiofrequency was performed in five cases. 56/61 (80%) patients received chemotherapy, mostly FOLFOX protocol as the first-line treatment and targeted therapy in 55% of cases. For the overall population, median OS and PFS were, respectively, 44 and 32 months. We did not observe any significant difference in terms of OS (p = 0.659) and PFS (p = 0.318) between resected LM or/and PM. A better survival was found when there was disease-free interval between the occurrence of the primary and the metastases exceeded 18 months and in patients with less than four metastases. Conclusion: Resection of metastatic disease mostly in liver and lungs improves survival of patients with CRC. The patients with longer disease-free interval and less than four metastases had the best outcomes.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2018-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49051895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Berbée, A. Verrijssen, J. Buijsen, F. Verhaegen, E. V. Limbergen
{"title":"The role of external beam and endoluminal radiation boosting in rectal cancer","authors":"M. Berbée, A. Verrijssen, J. Buijsen, F. Verhaegen, E. V. Limbergen","doi":"10.2217/CRC-2019-0006","DOIUrl":"https://doi.org/10.2217/CRC-2019-0006","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2019-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48059733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Mostafa, Enas F Abdel Hamed, E. Fawzy, R. Zalat, H. Rashed, S. Mohamed
Aim: Cryptosporidiosis causes colon dysplasia. This research aimed to evaluate the effect of a novel combination between artesunate and nitazoxanide on intensity of infection and the resulting intestinal dysplasia. Materials & methods: Subjects were divided into five groups. Artesunate was used alone, then combined with nitazoxanide. Results: The highest efficacy in reducing oocyst shedding obtained from the combined therapy (68.5, 75.9, 99%) after 7, 14 and 21 days. The histopathology of infected colonic mucosa showed marked improvement and low-grade of dysplasia in the infected and treated group with the combined therapy. The immunohistochemistry of the same group revealed mild dysplastic changes in colonic epithelium without nuclear expression for cyclin D1. Conclusion: These results give hope for treatment of Cryptosporidium and improving intestinal dysplasia.
{"title":"The new trend in the treatment of experimental cryptosporidiosis and the resulting intestinal dysplasia","authors":"N. Mostafa, Enas F Abdel Hamed, E. Fawzy, R. Zalat, H. Rashed, S. Mohamed","doi":"10.2217/CRC-2018-0008","DOIUrl":"https://doi.org/10.2217/CRC-2018-0008","url":null,"abstract":"Aim: Cryptosporidiosis causes colon dysplasia. This research aimed to evaluate the effect of a novel combination between artesunate and nitazoxanide on intensity of infection and the resulting intestinal dysplasia. Materials & methods: Subjects were divided into five groups. Artesunate was used alone, then combined with nitazoxanide. Results: The highest efficacy in reducing oocyst shedding obtained from the combined therapy (68.5, 75.9, 99%) after 7, 14 and 21 days. The histopathology of infected colonic mucosa showed marked improvement and low-grade of dysplasia in the infected and treated group with the combined therapy. The immunohistochemistry of the same group revealed mild dysplastic changes in colonic epithelium without nuclear expression for cyclin D1. Conclusion: These results give hope for treatment of Cryptosporidium and improving intestinal dysplasia.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2018-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42088988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Wegner, N. Ahmed, S. Hasan, James T McCormick, A. Kirichenko, A. Colonias
Aim: Stereotactic body radiotherapy (SBRT) has been used as an alternative to surgical intervention to treat primary malignanices of the lung as well as lesions from other primaries. In this study, we evaluate the safety and efficacy of SBRT in treating lung metastases from colorectal cancer (CRC). Materials & methods: We reviewed 22 patients that underwent lung SBRT for metastases from CRC. Almost all patients received chemotherapy before and after undergoing SBRT. Outcomes that were analyzed included overall survival, distant failure and progression-free survival, as well as the effects of biologically effective dose (BED) and KRAS status on local control. Results: Seven females and 15 males underwent SBRT to lung metastases from CRC. The median Eastern Cooperative Oncology Group status was one (0–2). The median dose was 48 Gy (40–54 Gy) in 5 fx (4–8 fx) and the median number of nodules treated with SBRT was one (1–3). Median follow-up was 28.5 months from SBRT and 79 months (9–145) from primary diagnosis. Local control at 1 and 3 years was 75 and 58%, respectively. There was a trend toward improved local control with increasing biologically effective dose (BED10 > 100; p = 0.07). Cancers that were positive for the KRAS mutation had increased local control at 12 months, 100 versus 75% (p = 0.0199). Median OS from the primary diagnosis of CRC and from SBRT was 79 and 31 months, respectively. There were no predictors for OS. There were no episodes of acute or late grade 3 or higher toxicity. Conclusion: The results of this study add to the growing body of literature to support SBRT for lung metastases, specifically those patients with limited lung metastases from CRC. The choice of radiation dose remains important, even in metastatic disease, as highlighted by the trend toward improved local control with increasing BED10.
{"title":"Stereotactic body radiotherapy for lung metastases from colorectal cancer: a single institution experience","authors":"R. Wegner, N. Ahmed, S. Hasan, James T McCormick, A. Kirichenko, A. Colonias","doi":"10.2217/CRC-2018-0005","DOIUrl":"https://doi.org/10.2217/CRC-2018-0005","url":null,"abstract":"Aim: Stereotactic body radiotherapy (SBRT) has been used as an alternative to surgical intervention to treat primary malignanices of the lung as well as lesions from other primaries. In this study, we evaluate the safety and efficacy of SBRT in treating lung metastases from colorectal cancer (CRC). Materials & methods: We reviewed 22 patients that underwent lung SBRT for metastases from CRC. Almost all patients received chemotherapy before and after undergoing SBRT. Outcomes that were analyzed included overall survival, distant failure and progression-free survival, as well as the effects of biologically effective dose (BED) and KRAS status on local control. Results: Seven females and 15 males underwent SBRT to lung metastases from CRC. The median Eastern Cooperative Oncology Group status was one (0–2). The median dose was 48 Gy (40–54 Gy) in 5 fx (4–8 fx) and the median number of nodules treated with SBRT was one (1–3). Median follow-up was 28.5 months from SBRT and 79 months (9–145) from primary diagnosis. Local control at 1 and 3 years was 75 and 58%, respectively. There was a trend toward improved local control with increasing biologically effective dose (BED10 > 100; p = 0.07). Cancers that were positive for the KRAS mutation had increased local control at 12 months, 100 versus 75% (p = 0.0199). Median OS from the primary diagnosis of CRC and from SBRT was 79 and 31 months, respectively. There were no predictors for OS. There were no episodes of acute or late grade 3 or higher toxicity. Conclusion: The results of this study add to the growing body of literature to support SBRT for lung metastases, specifically those patients with limited lung metastases from CRC. The choice of radiation dose remains important, even in metastatic disease, as highlighted by the trend toward improved local control with increasing BED10.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"1 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2018-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41653073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shinya Munakata, Yuta Murai, Akihiro Koiuzumi, H. Kato, Riku Yamamoto, Shuhei Ueda, S. Tokuda, Shunsuke Sakuraba, T. Kushida, H. Orita, M. Sakurada, H. Maekawa, Koich Sato
{"title":"Long-term outcomes of colorectal cancer patients with and without malignant large-bowel obstruction","authors":"Shinya Munakata, Yuta Murai, Akihiro Koiuzumi, H. Kato, Riku Yamamoto, Shuhei Ueda, S. Tokuda, Shunsuke Sakuraba, T. Kushida, H. Orita, M. Sakurada, H. Maekawa, Koich Sato","doi":"10.2217/CRC-2018-0001","DOIUrl":"https://doi.org/10.2217/CRC-2018-0001","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2018-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48004318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hamid Tanzadehpanah, H. Mahaki, M. Moradi, S. Afshar, O. Rajabi, R. Najafi, R. Amini, M. Saidijam
{"title":"Human serum albumin binding and synergistic effects of gefitinib in combination with regorafenib on colorectal cancer cell lines","authors":"Hamid Tanzadehpanah, H. Mahaki, M. Moradi, S. Afshar, O. Rajabi, R. Najafi, R. Amini, M. Saidijam","doi":"10.2217/CRC-2017-0018","DOIUrl":"https://doi.org/10.2217/CRC-2017-0018","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44505814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号